Cost Controls vs. Curing Citizens: Fallout from the U.K.

Just like the protagonist in "Fortunately, Unfortunately" Gilead Sciences (NASDAQ: GILD  ) is experiencing a disproportionate amount of highs and lows.

Fortunately, the big biotech released great phase 3 data out of Japan for an experimental hepatitis-c combo treatment of the approved Sovaldi and ledipasvir which saw 100% cure rates.

Unfortunately, the cost of the hep-C cure has created a intense backlash which has spread to the UK. Their health agency, NICE, said Sovaldi's $59,000 price tag, $25,000 less than we pay in the U.S., was likely still too high for the government to pay for in all but the most severe cases. 

In this episode of market checkup, the Motley Fool's health care focused investing show, analysts David Williamson and Michael Douglass discuss the highs and lows of Gilead's week and the important takeaways for investors.

 

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need to Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

  


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 24, 2014, at 10:17 AM, dbdude wrote:

    Only problem with NICE logic is the less severe cases are the ones you want to address FIRST as then they don't develop into severe cases with costly complications. These complications will cost far more than the cure... and you might also want to consider that MANY MORE PEOPLE WILL LIVE - or maybe they don't care about that. DUH...

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3005077, ~/Articles/ArticleHandler.aspx, 12/17/2014 3:08:27 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement